Science

Novateur Ventures explores new strategy to reduce hyperinflammatory response caused by COVID-19

Novateur Ventures explores new strategy to reduce hyperinflammatory response caused by COVID-19

Novateur’s research proposes simple treatment paradigm using two generic drugs, directed to blocking inflammation in airways of patients with asthma, to target hyper-inflammatory response insevere COVID-19. This will be accomplished by combination of leukotriene biosynthesis blocker zileuton (Zyflo® controlled release formulation) and inhibitor of cysteinyl leukotriene 1 receptor montelukast (Singulair®). Both these agents have been on market for many years, and their activity and side effects in humans are well known.

Read More…….
EurekAlert!, the online, global news service operated by AAAS, the science society,